Arsenic trioxide newly joins treatment strategies for acute promyelocytic leukemia.
Kuriyama
K
K
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D020261:Arsenic Poisoning / Q000209:etiology; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D010087:Oxides / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide